Abstract
Aim: To discuss the diagnosis and treatment of superior vein thrombosis in a patient who has hereditary thrombophilia, to point out the importance of preventive treatment in these patients.
Materials and Methods: We investigated the whole peroperative period in a patient who underwent emergency surgical treatment for superior mesenteric vein thrombosis due to prothrombin 20210 G/A and MTHFR C677T mutations.
Results: We performed partial small bowel resection and primary anastomosis laparoscopically with the diagnosis of superior mesenteric vein thrombosis. Oral anticoagulation treatment was initiated at the postoperative period. The patient was discharged without any problem.
Conclusion: Although it is quite rare, prothrombin 20210 G/A and MTHFR C677T mutations may be found in Turkish population. In patients who have multiple thrombotic events, prothrombin 20210 G/A and MTHFR C677T mutations should be considered. Life-time oral anticoagulation therapy is important in these patients.
Keywords:
Superior mesenteric vein thrombosis, prothrombin 20210 G/A mutation, methylenetetrahydrofolate reductase C677T mutation
References
1Kumar S, Sarr MG, Kamath PS.Mesenteric venous thrombosis. N Engl J Med 2001; 345: 1683-1688. DOI:10.1056/NEJMra010076
2Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase C677T, and population genetics. Mol Genet Metab 2205;86:91-99.
3Mainwaring CJ, Makris M, Thomas WE, Hampton KK, Preston FE. Mesenteric infarction due to combined protein C deficiency and protrombin 20210 defects. Postgrad Med J 1999;75:742-743.
4Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231. DOI:10.1056/ NEJM200104193441607
5Agaoglu N, Turkyilmaz S, Ovali E, Ucar F, Agaoglu C. Prevalence of prothrombotic abnormalities in patients with acute mesenteric ischemia. World J Surg 2005;29:1135-1138.
6Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, Den Heijer M, Kluijtmans LAJ, Van den Heuvel LP, Rozen R, A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
7Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variatiton in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
8Van der Meer FJ, Koster T, Vanderbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-635.
9Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-708.
10Gurgey A, Haznedaroglu IC, Egesel T, Buyukasik Y, Ozcebe OI, Sayinalp N, et al.Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol 2001;67:107-111. DOI:10.1002/ajh.1087
11Karakus Z, Baslamisli F, Gurkan E, Guvenc B, Unsal C, Tanriverdi K. Thrombophilic risk factors in patients with venous thrombosis (in Turkish). XXIX National Congress of Hematology; 2002.
12Ozmen F, Ozmen MM, Ozalp N, Akar N. The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. Ulus Travma Acil Cerrahi Derg 2009;15:113-119.
13Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 1998; 58: 249. DOI: 10.1002/ (SICI)1096-8652(199807)58:3<249::AIDAJH20>3.0.CO;2-3
14Bauer KA. The thrombophilias; well-defined risk factor with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-373.
15Liem TK, DeLoughery TG. First episode and recurrent venous thromboembolism: Who is identifiably at risk? Semin Vasc Surg 2008; 21: 132-138. DOI:10.1053/j. semvascsurg.2008.05.006
16Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401S-428S (suppl). DOI:10.1378/chest.126.3_suppl.401S
17Karagulle E, Turk E, Gokturk HS, Yildirim E, Moray G. Prothrombin 20210 G/A defect as a cause of mesenteric venous infarction: report of a case. Surg Today 2007; 37: 251-253. DOI:10.1007/s00595- 006-3381-8
